2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome
Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome. Molecular Cancer Therapeutics 2021, 20: 1422-1430. PMID: 34108263, PMCID: PMC8941846, DOI: 10.1158/1535-7163.mct-20-0377.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntimetabolites, AntineoplasticApoptosisAzacitidineBiomarkers, TumorCell ProliferationDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationEpigenesis, GeneticEpigenomeGene Expression ProfilingGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansImmunityLymphoma, T-CellMaleTestisTumor Cells, CulturedConceptsEpigenetic geneHistone deacetylaseSuppression of genesHDAC inhibitorsDNA methyltransferase inhibitorTranscriptional inductionDNA methylationMaster regulatorDNMT inhibitorsEpigenetic diseasePeripheral T-cell lymphomaGene expressionMethyltransferase inhibitorMechanistic basisCell deathGenesCancer-testis antigensTestis antigensEpigenomeMutationsCholesterol metabolismInhibitorsInductionMatrisomeTh1-like phenotype
2020
The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaGrade 3 hyponatremiaPhase 1b studyTreatment-related deathsGrade 3 thrombocytopeniaImmune checkpoint inhibitorsPreliminary clinical dataDose of drugPre-clinical modelsCancer-testis antigensCases of toxicityExperienced progressionFebrile neutropeniaRefractory PTCLStable diseaseComplete remissionPartial remissionPatient characteristicsClinical dataPharmacodynamic studiesTestis antigensPatientsTriple combinationResponse rate
2018
Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)
Falchi L, Lue J, Montanari F, Marchi E, Amengual J, Sawas A, Deng C, Khan K, Kim H, Atkins L, Rada A, Serge C, O'Connor O. Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 2018, 132: 1002. DOI: 10.1182/blood-2018-99-116605.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaDuration of responseAdverse eventsHypomethylating agentR Peripheral T Cell LymphomaResponse rateMedian DORHigh complete response ratePhase 2Dose-escalation portionG1-2 toxicitiesNausea/vomitingPhase 1 patientsPhase 2 doseComplete response ratePhase 1/2 trialProgression-free survivalOverall response rateTreatment-naïve individualsNon-T-cell lymphomasCancer-testis antigensB-cell lymphomaCombination of AZA